Inclusion Criteria:  Adult patients ≥ 18 years at AML diagnosis Patients that started gilteritinib during ATU and post-ATU period from 19th March 2019 to 30th March2021 Patients diagnosed with refractory or relapsed AML as defined by the World Health Organization (WHO) Classification Patients with FLT3 genetic testing performed at diagnosis and/or at R/R (if available) Gilteritinib with or without other drug (chemotherapy, hypomethylating agent, hydroxyurea, etc.)  Exclusion Criteria:  Newly diagnosed AML patients Participant opposed to the collection and analysis of their medical data Prescription of gilteritinib out of the scope of its marketing authorisation approval such as post HSCT maintenance in patients in first complete remission after intensive chemotherapy persons placed in curatorship,guardianship or guardianship orders